Key result
Low-dose rivaroxaban plus aspirin cuts all-cause mortality ~12% vs aspirin in CAD but increases major bleeding.
Why the study?
The survival advantage and risk-benefit profile of combining low-dose rivaroxaban with aspirin in patients with CAD remained uncertain.
Does low-dose rivaroxaban plus aspirin reduce all-cause mortality, myocardial infarction, and stroke in patients with coronary artery disease compared to aspirin monotherapy?
Meta-Analysis (n=41,351)
Does low-dose rivaroxaban plus aspirin reduce all-cause mortality, myocardial infarction, and stroke in patients with coronary artery disease compared to aspirin monotherapy?
Effect estimate: HR 0.88 (95% CI 0.81-0.95)
p-value: p=0.002
Low-dose rivaroxaban combined with aspirin provides survival benefits and reduces the risk of myocardial infarction and stroke in patients with coronary artery disease, though it increases the risk of major bleeding.
Supports adding low-dose rivaroxaban to aspirin in CAD; confirms mortality benefit while underscoring bleeding trade-off.
INTRODUCTION: Despite advancements in coronary artery disease (CAD) management, major adverse cardiovascular events persist. Vitamin K antagonists and direct oral anticoagulants present bleeding risks. Low-dose rivaroxaban (2.5 mg) is approved by the European Society of Cardiology and the US Food and Drug Administration for CAD. The survival advantage and risk-benefit profile of combining low-dose rivaroxaban with aspirin for CAD patients remain uncertain. This meta-analysis aims to compare the efficacy of low-dose rivaroxaban plus aspirin versus aspirin monotherapy in CAD patients. METHODS: We systematically searched databases for randomized controlled trials exploring low-dose rivaroxaban with aspirin in CAD patients. Of the 6220 studies screened, five met the inclusion criteria. Primary outcomes included myocardial infarction, stroke, major bleeding events, and all-cause mortality. The analysis employed a fixed-effects model, calculating hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: Five randomized controlled trials involving 41,351 participants were included. Rivaroxaban (2.5 mg) significantly reduced all-cause mortality (HR, 0.88; 95% CI, 0.81-0.95; P = 0.002), myocardial infarction (HR, 0.81; 95% CI, 0.70-0.94; P = 0.006), and stroke (HR, 0.61; 95% CI, 0.49-0.76; P < 0.00001) compared to aspirin alone. However, it increased major bleeding risk (HR, 1.66; 95% CI, 1.40-1.97; P < 0.01). Meta-regression revealed no dose-dependent impact on all-cause mortality. CONCLUSION: Low-dose rivaroxaban demonstrates survival benefits and reduces myocardial infarction and stroke risks in CAD patients, albeit with an increased risk of major bleeding. Consideration of patient bleeding risk is crucial when adding rivaroxaban to antiplatelet therapy. Further research is warranted to compare its effectiveness and safety with dual antiplatelet therapy or P2Y12 inhibitors.
No takes yet. Share an insight, caveat, or question.
Hennawi et al. (2024) conducted a meta-analysis in coronary artery disease (n=41,351). low-dose rivaroxaban plus aspirin vs. aspirin alone was evaluated on all-cause mortality (HR 0.88, 95% CI 0.81-0.95, p=0.002). Low-dose rivaroxaban plus aspirin significantly reduced all-cause mortality (HR 0.88; 95% CI 0.81-0.95; P=0.002), MI, and stroke in CAD patients compared to aspirin alone, but increased major bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: